Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Sep
Source: Bse
Virinchi Limited (VIRINCHI)
Small CapIT stocks · Small cap · NSE
Virinchi Limited operates in Healthcare IT, within the IT sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
₹12.95
-0.64 · -4.71%
Market cap ₹144 Cr
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals06 Oct 2026 · screener
Latest result13 Aug, 08:04 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · IT P/E 21.4 (n=204)
Technical timing lens
Trend score and candlestick chart
56Neutralfull bear SMA stack · SMA20 -8.5% / mo · MACD + · near 52W low · sector +14.5pp vs Nifty 500 (3M)
Stock trend: 26
Sector RS: 100
Sector 3M: +8.9% vs Nifty 500 -5.6%
IT FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
VIRINCHID candles · FIT view-27.1%Latest close ₹12.95 on 2026-10-19
Bar
-8.2%
RSI
41
MACD hist
0.08
52W pos
4%
2026-10-19O ₹14.10H ₹14.10L ₹12.70C ₹12.95Vol 59,075 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
VIRINCHINifty ITNifty 500
- VIRINCHI
- -20.3%
- Nifty 500
- -5.6%
- Nifty IT
- +8.1%
- Vs Nifty 500
- -14.7 pp
Chart stats
19 Oct 2026- From 52W high
- -56.1%
- 52W range position
- 4%
- ATR (14)
- 6.3%
- Volume vs 20D
- 0.99x
- Avg traded value
- ₹0.1 Cr
- 20D price channel
- ₹12.3 - ₹14.5
₹29.5
₹12.3 - ₹29.5
₹0.8
Latest completed session
20-session average
39.7% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Verify management risk first
Do not let cheap valuation override weak Trust or governance evidence.
U-Score
Legacy · OVERVALUED10
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue -12.1% · PAT -667.6% YoY
Technical
Neutral56
Price trend and sector-relative-strength timing.
Valuation
Legacy model—
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence49
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100Rev -12% YoY · PAT -668% YoY · margin compression · +6% QoQ
Filed 13 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹70.1 Cr | -12.1% | +6.3% |
| EBITDA | ₹14.9 Cr | -42.9% | +595.3% |
| Operating margin | 21.2% | -1149 bps | +1798 bps |
| PAT | ₹-2.1 Cr | -667.6% | NDF |
| PAT margin | -3.0% | -345 bps | +2078 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- —
- P/B
- 0.28
- EV/EBITDA
- 3.83
- Market Cap
- 144.00Cr
Profitability
- ROE
- -4.67%
- ROCE
- 2.12%
- ROA
- -3.53%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- -4.00%
- EPS 5Y
- -16.00%
- Revenue 3Y
- -3.00%
- EPS 3Y
- -29.00%
Balance Sheet
- Debt/Equity
- 0.55
- Interest Coverage
- 1.66×
- Altman Z
- 1.61
- Book Value
- 45.30
Cash Flow
- FCF Yield
- 1.39%
- FCF Positive Y
- 6/5
- OCF
- 21.00 Cr
- EPS TTM
- -2.46
Shareholding
- Promoter Hold
- 39.46%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 1%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 70.1+6.3% vs prev
Net Profit
₹ CrLatest: -2.1+86.6% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 41. Wait for confirmation.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~9.3% over last month) — short-term momentum negative.
- RSI(14) at 41 — rising, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 56% off 52W high · 6% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
7
RS percentile
Stage 4 Downtrend
1M return
-8.6%
3M return
-20.3%
6M return
-28.5%
1Y return
-53.7%
RS 1D
-2
RS 20D
-1
Sector rank
#8
Industry rank
#39
Stage evidence
- Price is 17.8% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -4.4%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
improving
Industry
improving
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 48.44-3.72%
RS vs Nifty 50048
Valuation & peers
U-Score 10 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 10 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Distress Watch
Fundamental score breakdown
U band · OVERVALUEDValuation7/30
Growth2/25
Quality0/20
Balance Sheet2/15
Cash Flow5/10
Piotroski
4/9 (+1)
Penalties
-7
Raw sum
10
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
10/100 · legacy band OVERVALUED
Positive drivers
- Cash flow contributes 5/10 to the score.
- Valuation contributes 7/30 to the score.
- Balance sheet contributes 2/15 to the score.
Main drags
- Altman Z is 1.6, in distress territory.
- Penalty bucket subtracts 7 points.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
—
PB
0.3
EV/EBITDA
3.8
ROE
-4.7%
ROCE
2.1%
FCF Yield
1.4%
Debt/Equity
0.6
MoS
—
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
10
Previous: 10
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
—
No stored baseline yet
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
10
10
10
10
10
10
10
10
10
10
10
10
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
—
Growth-justified P/E
2.9
Growth-justified Value
—
— MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in IT — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
HVAX
SME
HVAX Technologies Ltd.
IT Services / Digital
match 146
57
14.7
18.0%
+56%
FAIR VALUE
IKS
Small
Inventurus Knowledge Solutions Limited
IT Services / Digital
match 138
58
38.9
31.4%
-18%
FAIR VALUE
HGM
Small
HandsOn Global Management (HGM) Limited
IT Services / Digital
match 125
8
—
-13.8%
—
OVERVALUED
AAKAAR
SME
Aakaar Medical Technologies Ltd.
IT Services / Digital
match 119
55
15.2
17.1%
+55%
FAIR VALUE
FABTECH
Small
Fabtech Technologies Limited
IT Services / Digital
match 110
61
12.9
12.5%
+69%
UNDERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Virinchi Limited operates in Healthcare IT, within the IT sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
49Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 6th percentile of the scored universe and 6th percentile within IT. Main check: results consistency is weak at 5/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
40 docs text-extracted · 11 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
6th percentile
overall median 67 · IT: 6th pctile, median 69 · Small: 7th pctile, median 66
Evidence depth
Financial-only
40 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
82
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
33
weak · leverage and solvency
Discipline
30
weak · capital discipline
Results
5
weak · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸Promoter holding increased 2%.
- ▸FCF yield is positive at 1.2%.
- ▸6 years of positive FCF.
Trust risks
- ▸Altman Z is 1.65.
- ▸4 latest quarters had PAT decline worse than 25% YoY.
- ▸Interest coverage is 1.7x.
- ▸ROCE is low at 1.3%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Virinchi Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Aug
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 11 Jul - The News Paper Publication Regarding the dispatch of Postal Ballot Notice
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Acquisition 9 Jul - Board approved ₹100 crore slump-sale acquisition of Bristlecone Hospitals business from subsidiary VHCPL, subject to shareholder approval.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.